Recombinant Human Caspr2 His-tag Protein, CF

Recombinant Human Caspr2 His-tag (Catalog # 8207-CRB ) has a molecular weight (MW) of 170.2 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (e.g. Glycosylation).

Measured by its binding ability in a functional ELISA. Recombinant Human Caspr2 His-tag Protein (Catalog # 8207-CRB) binds to Recombinant Human Contactin-2/TAG1 Protein ( 1714-CN) with an ED50 of 0.400-4.00 µg/mL.

2 μg/lane of Recombinant Human Caspr2 His-tag Protein (Catalog # 8207-CRB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 130-150 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Caspr2 His-tag Protein, CF Summary

• Additional Information: Analyzed by SEC-MALS
• Details of Functionality: Measured by its binding ability in a functional ELISA. Recombinant Human Caspr2 His-tag binds to Recombinant Human Contactin-2/TAG1 Protein (Catalog # 1714-CN) with an ED₅₀ of 0.400-4.00 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human Caspr2 protein
  Ala28-Ala1262, with a C-terminal 6-His tag
• Accession #: Q9UHC6.1
• N-terminal Sequence: Ala 28
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 138 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 130-150 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 100 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Caspr2 His-tag Protein, CF

• AUTS15
• Caspr2
• CASPR2DKFZp781D1846
• CDFE
• Cell recognition molecule Caspr2
• CNTNAP2
• contactin associated protein-like 2
• contactin-associated protein 2
• contactin-associated protein-like 2
• homolog of Drosophila neurexin IV
• KIAA0868
• NRXN4
• NRXN4Caspr2
• PTHSL1

Background

Contact-associated Protein-like 2 (Caspr2) is a type I transmembrane member of the neurexin family of adhesion molecules (1). Human Caspr2 is the vertebrate homolog to Drosophila Neurexin IV, and the human and mouse Caspr2 orthologs share 94% amino acid sequence identity. Human Caspr2 contains two EGF-like domains, one F5/8 type C domain, one fibrinogen C-terminal domain, and four laminin G-like domains. It is highly expressed in neuronal tissue where it is primarily localized to the juxtaparanodal region of the axonal membrane (1, 2). Caspr2 acts in conjunction with 4.1B and Tag-1 as a scaffold that clusters Kv1 potassium channels at the juxtaparanodal region and is critical for axo-glial contacts (1-6). Caspr2 interacts with carboxypeptidase E in Golgi bodies during intracellular trafficking to the cell membrane (7). Caspr2 is also required for dendrite arborization and the normal development of neural networks (8). Mutations in Caspr2 are associated with predisposition to autism spectrum disorders, epilepsy, attention-deficit hyperactive disorder, and schizophrenia (8-11). The presence of autoantibodies against Caspr2 is associated with encephalitis, epilepsy, dysarthria, and paroxysmal kinesigenic dystonia (12-14). R&D Systems in-house testing indicates that Caspr2 can enhance bovine corneal endothelial cell adhesion.

1. Poliak, S. et al. (1999) Neuron 24:1037.
2. Poliak, S. et al. (2001) J. Neurosci. 21:7568.
3. Horresh, I. et al. (2010) J. Neurosci. 30:2480.
4. Traka, M. et al. (2003) J. Cell Biol. 162:1161.
5. Denisenko-Nehrbass, N. et al. (2003) Eur. J. Neurosci. 17:411.
6. Poliak, S. et al. (2003) J. Cell Biol. 162:1149.
7. Oiso, S. et al. (2009) J. Neurochem. 109:158.
8. Anderson, G.R. et al. (2012) Proc. Natl. Acad. Sci. USA 109:18120.
9. Penagarikano, O. and D.H. Geschwind (2012) Trends Mol. Med. 18:156.
10. Friedman, J.I. et al. (2008) Mol. Psychiatry 13:261.
11. Elia, J. et al. (2010) Mol. Psychiatry 15:637.
12. Lancaster, E. et al. (2011) Ann. Neurol. 69:303.
13. Balint, B. et al. (2013) J. Neurol. Sci. 327:73.
14. Krogias, C. et al. (2013) JAMA Neurol. 70:1056.

Bioinformatics

• Uniprot:
  • Q9UHC6.1()